The infectious burden in atherothrombosis

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 5, 2012, Pages 515-523

  Tufano, Antonella ^a   Di Capua, Mirko ^a   Coppola, Antonio ^a   Conca, Paolo ^a   Cimino, Ernesto ^a   Cerbone, Anna Maria ^a   Di Minno, Giovanni ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

atherosclerosis; cardiovascular disease; infection; infectious burden; inflammation

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; PLACEBO;

ANTIBIOTIC THERAPY; ARTICLE; ATHEROSCLEROSIS; BORRELIA BURGDORFERI; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY DISEASE; CYTOMEGALOVIRUS; ENTEROVIRUS; EPSTEIN BARR VIRUS; HEART INFARCTION; HELICOBACTER PYLORI; HEPATITIS VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN PARVOVIRUS B19; INFLUENZA VIRUS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PATHOGEN LOAD; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; THROMBOSIS; BLOOD; INFECTION; MICROBIOLOGY; REVIEW; RISK FACTOR;

ATHEROSCLEROSIS; HUMANS; INFECTION; RISK FACTORS; THROMBOSIS;

EID: 84872909504     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1315759     Document Type: Article

References (111)

1. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med: 1999; 340 2 115 126
2. Libby P., Ridker P. M., Maseri A. Inflammation and atherosclerosis. Circulation: 2002; 105 9 1135 1143 (Pubitemid 34212626)
3. Kol A., Libby P. The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations. Trends Cardiovasc Med: 1998; 8 5 191 199 (Pubitemid 28345822)
4. O'Connor S., Taylor C., Campbell L. A., Epstein S., Libby P. Potential infectious etiologies of atherosclerosis: a multifactorial perspective. Emerg Infect Dis: 2001; 7 5 780 788 (Pubitemid 33121582)
5. Kalayoglu M. V., Libby P., Byrne G. I. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA: 2002; 288 21 2724 2731 (Pubitemid 35403786)
6. Rosenfeld M. E., Campbell L. A. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost: 2011; 106 5 858 867
7. Jiang B., Hebert V. Y., Khandelwal A. R., Stokes K. Y., Dugas T. R. HIV-1 antiretrovirals induce oxidant injury and increase intima-media thickness in an atherogenic mouse model. Toxicol Lett: 2009; 187 3 164 171
8. Jiang B., Khandelwal A. R., Rogers L. K., et al. Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. Toxicol Sci: 2010; 117 2 524 536
9. Elkind M. SV. Infectious burden: a new risk factor and treatment target for atherosclerosis. Infect Disord Drug Targets: 2010; 10 2 84 90
10. Elkind M. SV, Luna J. M., Moon Y. P., et al. Infectious burden and carotid plaque thickness: the northern Manhattan study. Stroke: 2010; 41 3 e117 e122
11. Elkind M. SV. Inflammatory mechanisms of stroke. Stroke: 2010; 41 10 S3 S8
12. Zhu J., Quyyumi A. A., Norman J. E., et al. Effects of total pathogen burden on coronary artery disease risk and C-reactive protein levels. Am J Cardiol: 2000; 85 2 140 146 (Pubitemid 30026092)
13. Vink A., Poppen M., Schoneveld A. H., et al. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual. Circulation: 2001; 103 12 1613 1617 (Pubitemid 32246606)
14. Virok D., Kis Z., Karai L., et al. Chlamydia pneumoniae in atherosclerotic middle cerebral artery. Stroke: 2001; 32 9 1973 1976 (Pubitemid 32868082)
15. Shor A., Kuo C. C., Patton D. L. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J: 1992; 82 3 158 161
16. Maass M., Bartels C., Engel P. M., Mamat U., Sievers H. H. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol: 1998; 31 4 827 832 (Pubitemid 28186419)
17. Jackson L. A., Campbell L. A., Kuo C. C., Rodriguez D. I., Lee A., Grayston J. T. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis: 1997; 176 1 292 295 (Pubitemid 27272888)
18. Danesh J., Collins R., Peto R. Chronic infections and coronary heart disease: is there a link? Lancet: 1997; 350 9075 430 436 (Pubitemid 27331246)
19. Mosorin M., Surcel H. M., Laurila A., et al. Detection of Chlamydia pneumoniae -reactive T lymphocytes in human atherosclerotic plaques of carotid artery. Arterioscler Thromb Vasc Biol: 2000; 20 4 1061 1067 (Pubitemid 30207583)
20. Benagiano M., D'Elios M. M., Amedei A., et al. Human 60-kDa heat shock protein is a target autoantigen of T cells derived from atherosclerotic plaques. J Immunol: 2005; 174 10 6509 6517 (Pubitemid 40663846)
21. Kern J. M., Maass V., Maass M. Chlamydia pneumoniae adversely modulates vascular cell properties by direct interaction with signalling cascades. Thromb Haemost: 2009; 102 6 1064 1070
22. Campbell L. A., Yaraei K., Van Lenten B., et al. The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis. Microbes Infect: 2010; 12 8-9 598 606
23. Naiki Y., Sorrentino R., Wong M. H., et al. TLR/MyD88 and liver X receptor alpha signaling pathways reciprocally control Chlamydia pneumoniae -induced acceleration of atherosclerosis. J Immunol: 2008; 181 10 7176 7185
24. Chen S., Sorrentino R., Shimada K., et al. Chlamydia pneumoniae -induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation. J Immunol: 2008; 181 10 7186 7193
25. Erkkilä L., Laitinen K., Haasio K., et al. Heat shock protein 60 autoimmunity and early lipid lesions in cholesterol-fed C57BL/6JBom mice during Chlamydia pneumoniae infection. Atherosclerosis: 2004; 177 2 321 328 (Pubitemid 39505264)
26. Nakano K., Inaba H., Nomura R., et al. Detection of cariogenic Streptococcus mutans in extirpated heart valve and atheromatous plaque specimens. J Clin Microbiol: 2006; 44 9 3313 3317 (Pubitemid 44413770)
27. Kozarov E., Sweier D., Shelburne C., Progulske-Fox A., Lopatin D. Detection of bacterial DNA in atheromatous plaques by quantitative PCR. Microbes Infect: 2006; 8 3 687 693
28. Trevisan M., Dorn J. The relationship between periodontal disease (PD) and cardiovascular disease (CVD). Mediterr J Hematol Infect Dis: 2010; 2 3 e2010030
29. Teles R., Wang C. Y. Mechanisms involved in the association between periodontal diseases and cardiovascular disease. Oral Dis: 2011; 17 5 450 461
30. Glurich I., Grossi S., Albini B., et al. Systemic inflammation in cardiovascular and periodontal disease: comparative study. Clin Diagn Lab Immunol: 2002; 9 2 425 432 (Pubitemid 34226042)
31. Buhlin K., Hultin M., Norderyd O., et al. Periodontal treatment influences risk markers for atherosclerosis in patients with severe periodontitis. Atherosclerosis: 2009; 206 2 518 522
32. Lalla E., Lamster I. B., Hofmann M. A., et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol: 2003; 23 8 1405 1411 (Pubitemid 36994529)
33. Madan M., Bishayi B., Hoge M., Messas E., Amar S. Doxycycline affects diet- and bacteria-associated atherosclerosis in an ApoE heterozygote murine model: cytokine profiling implications. Atherosclerosis: 2007; 190 1 62 72 (Pubitemid 44908323)
34. Hayashi C., Viereck J., Hua N., et al. Porphyromonas gingivalis accelerates inflammatory atherosclerosis in the innominate artery of ApoE deficient mice. Atherosclerosis: 2011; 215 1 52 59
35. Li L., Messas E., Batista E. L. Jr, Levine R. A., Amar S. Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein E-deficient murine model. Circulation: 2002; 105 7 861 867 (Pubitemid 34174928)
36. Hayashi C., Madrigal A. G., Liu X., et al. Pathogen-mediated inflammatory atherosclerosis is mediated in part via toll-like receptor 2-induced inflammatory responses. J Innate Immun: 2010; 2 4 334 343
37. Griffiths R., Barbour S. Lipoproteins and lipoprotein metabolism in periodontal disease. Clin Lipidol: 2010; 5 3 397 411
38. Ameriso S. F., Fridman E. A., Leiguarda R. C., Sevlever G. E. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Stroke: 2001; 32 2 385 391 (Pubitemid 32155223)
39. Kaplan M., Yavuz S. S., Cinar B., et al. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Int J Infect Dis: 2006; 10 2 116 123 (Pubitemid 43255598)
40. Kowalski M. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque. J Physiol Pharmacol: 2001; 52 01 3 31 (Pubitemid 33730854)
41. Latsios G., Saetta A., Michalopoulos N. V., Agapitos E., Patsouris E. Detection of cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae DNA in carotid atherosclerotic plaques by the polymerase chain reaction. Acta Cardiol: 2004; 59 6 652 657 (Pubitemid 39619972)
42. Brenner H., Berg G., Fröhlich M., Boeing H., Koenig W. Chronic infection with Helicobacter pylori does not provoke major systemic inflammation in healthy adults: results from a large population-based study. Atherosclerosis: 1999; 147 2 399 403 (Pubitemid 29512272)
43. Elizalde J. I., Pérez-Pujol S., Heras M., et al. Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes. Helicobacter: 2004; 9 6 681 689 (Pubitemid 40023728)
44. Stone A. F., Mendall M. A., Kaski J-C., et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation: 2002; 106 10 1219 1223 (Pubitemid 34988639)
45. Rafferty B., Dolgilevich S., Kalachikov S., et al. Cultivation of Enterobacter hormaechei from human atherosclerotic tissue. J Atheroscler Thromb: 2011; 18 1 72 81
46. Völzke H., Wolff B., Lüdemann J., et al. Seropositivity for anti-Borrelia IgG antibody is independently associated with carotid atherosclerosis. Atherosclerosis: 2006; 184 1 108 112 (Pubitemid 41721076)
47. Fateh-Moghadam S., Bocksch W., Wessely R., Jäger G., Hetzer R., Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation: 2003; 76 10 1470 1474 (Pubitemid 37467696)
48. Grattan M. T., Moreno-Cabral C. E., Starnes V. A., Oyer P. E., Stinson E. B., Shumway N. E. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA: 1989; 261 24 3561 3566 (Pubitemid 19155945)
49. Roberts E. T., Haan M. N., Dowd J. B., Aiello A. E. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol: 2010; 172 4 363 371
50. Haji S. A., Starling R. C., Avery R. K., et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant: 2004; 23 3 277 283 (Pubitemid 38333084)
51. Boddi M., Abbate R., Chellini B., et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol: 2010; 47 1 72 75
52. Boddi M., Abbate R., Chellini B., et al. HCV infection facilitates asymptomatic carotid atherosclerosis: preliminary report of HCV RNA localization in human carotid plaques. Dig Liver Dis: 2007; 39 01 S55 S60 (Pubitemid 47528195)
53. Warren-Gash C., Smeeth L., Hayward A. C. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis: 2009; 9 10 601 610
54. Naghavi M., Wyde P., Litovsky S., et al. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Circulation: 2003; 107 5 762 768 (Pubitemid 36222607)
55. Van Lenten B. J., Wagner A. C., Anantharamaiah G. M., et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation: 2002; 106 9 1127 1132 (Pubitemid 34970855)
56. Haidari M., Wyde P. R., Litovsky S., et al. Influenza virus directly infects, inflames, and resides in the arteries of atherosclerotic and normal mice. Atherosclerosis: 2010; 208 1 90 96
57. Van Lenten B. J., Wagner A. C., Nayak D. P., Hama S., Navab M., Fogelman A. M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation: 2001; 103 18 2283 2288 (Pubitemid 32433719)
58. Hulten E., Mitchell J., Scally J., Gibbs B., Villines T. C. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. Heart: 2009; 95 22 1826 1835
59. Behrens G. M., Stoll M., Schmidt R. E. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf: 2000; 23 1 57 76 (Pubitemid 30455917)
60. Asztalos B. F., Schaefer E. J., Horvath K. V., et al. Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis: 2006; 184 1 72 77 (Pubitemid 41721071)
61. Kwon T. W., Kim D. K., Ye J. S., et al. Detection of enterovirus, cytomegalovirus, and Chlamydia pneumoniae in atheromas. J Microbiol: 2004; 42 4 299 304 (Pubitemid 40137894)
62. Liu S. C., Tsai C. T., Wu C. K., et al. Human parvovirus b19 infection in patients with coronary atherosclerosis. Arch Med Res: 2009; 40 7 612 617
63. Benditt E. P., Barrett T., McDougall J. K. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A: 1983; 80 20 6386 6389 (Pubitemid 14229080)
64. Lu M., Shenk T. Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S. J Virol: 1996; 70 12 8850 8857 (Pubitemid 26378468)
65. Khachigian L. M., Lindner V., Williams A. J., Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science: 1996; 271 5254 1427 1431 (Pubitemid 26089480)
66. Bavendiek U., Libby P., Kilbride M., Reynolds R., Mackman N., Schönbeck U. Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1. J Biol Chem: 2002; 277 28 25032 25039 (Pubitemid 34951807)
67. Chahine M. N., Deniset J., Dibrov E., et al. Oxidized LDL promotes the mitogenic actions of Chlamydia pneumoniae in vascular smooth muscle cells. Cardiovasc Res: 2011; 92 3 476 483
68. Zhou Y. F., Yu Z. X., Wanishsawad C., Shou M., Epstein S. E. The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Biochem Biophys Res Commun: 1999; 256 3 608 613 (Pubitemid 29301154)
69. Nelken N. A., Coughlin S. R., Gordon D., Wilcox J. N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest: 1991; 88 4 1121 1127
70. Ylä-Herttuala S., Lipton B. A., Rosenfeld M. E., Goldberg I. J., Steinberg D., Witztum J. L. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A: 1991; 88 22 10143 10147 (Pubitemid 21915791)
71. Boring L., Gosling J., Cleary M., Charo I. F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature: 1998; 394 6696 894 897 (Pubitemid 28410911)
72. Gu L., Okada Y., Clinton S. K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell: 1998; 2 2 275 281 (Pubitemid 128373654)
73. Krüll M., Maass M., Suttorp N., Rupp J. Chlamydophila pneumoniae. Mechanisms of target cell infection and activation. Thromb Haemost: 2005; 94 2 319 326
74. Krüll M., Klucken A. C., Wuppermann F. N., et al. Signal transduction pathways activated in endothelial cells following infection with Chlamydia pneumoniae. J Immunol: 1999; 162 8 4834 4841 (Pubitemid 29314887)
75. Hsich E., Zhou Y. F., Paigen B., Johnson T. M., Burnett M. S., Epstein S. E. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis: 2001; 156 1 23 28 (Pubitemid 32429591)
76. Vliegen I., Duijvestijn A., Grauls G., Herngreen S., Bruggeman C., Stassen F. Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. Microbes Infect: 2004; 6 1 17 24 (Pubitemid 38114817)
77. Chee M. S., Bankier A. T., Beck S., et al. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr Top Microbiol Immunol: 1990; 154 125 169 (Pubitemid 20151030)
78. Streblow D. N., Soderberg-Naucler C., Vieira J., et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell: 1999; 99 5 511 520
79. Lalla E., Lamster I. B., Hofmann M. A., et al. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol: 2003; 23 8 1405 1411 (Pubitemid 36994529)
80. Van Lenten B. J., Wagner A. C., Nayak D. P., Hama S., Navab M., Fogelman A. M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation: 2001; 103 18 2283 2288 (Pubitemid 32433719)
81. Dechend R., Gieffers J., Dietz R., et al. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae -induced cell interaction and activation. Circulation: 2003; 108 3 261 265 (Pubitemid 36899013)
82. Buono C., Binder C. J., Stavrakis G., Witztum J. L., Glimcher L. H., Lichtman A. H. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A: 2005; 102 5 1596 1601 (Pubitemid 40209213)
83. De Palma R., Del Galdo F., Abbate G., et al. Patients with acute coronary syndrome show oligoclonal T-cell recruitment within unstable plaque: evidence for a local, intracoronary immunologic mechanism. Circulation: 2006; 113 5 640 646
84. Keller T. T., van der Meer J. J., Teeling P., et al. Selective expansion of influenza A virus-specific T cells in symptomatic human carotid artery atherosclerotic plaques. Stroke: 2008; 39 1 174 179
85. Perschinka H., Mayr M., Millonig G., et al. Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol: 2003; 23 6 1060 1065 (Pubitemid 36713561)
86. Sasu S., LaVerda D., Qureshi N., Golenbock D. T., Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res: 2001; 89 3 244 250 (Pubitemid 34132682)
87. Haralambieva I. H., Iankov I. D., Ivanova P. V., Mitev V., Mitov I. G. Chlamydophila pneumoniae induces p44/p42 mitogen-activated protein kinase activation in human fibroblasts through toll-like receptor 4. J Med Microbiol: 2004; 53 Pt 12 1187 1193 (Pubitemid 40052472)
88. Ford P. J., Gemmell E., Timms P., Chan A., Preston F. M., Seymour G. J. Anti- P. gingivalis response correlates with atherosclerosis. J Dent Res: 2007; 86 1 35 40
89. Ayada K., Yokota K., Hirai K., et al. Regulation of cellular immunity prevents Helicobacter pylori -induced atherosclerosis. Lupus: 2009; 18 13 1154 1168
90. Dentali F., Nicolini E., Ageno W. Venous and arterial thrombosis associated with HIV infection. Semin Thromb Hemost: 2012; 38 5 524 529
91. Behrens G. M., Stoll M., Schmidt R. E. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf: 2000; 23 1 57 76 (Pubitemid 30455917)
92. Asztalos B. F., Demissie S., Cupples L. A., et al. LpA-I, LpA-I:A-II HDL and CHD-risk: The Framingham offspring study and the veterans affairs HDL intervention trial. Atherosclerosis: 2006; 188 1 59 67 (Pubitemid 44142535)
93. Badiou S., Merle De Boever C., Dupuy A. M., Baillat V., Cristol J. P., Reynes J. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis: 2003; 168 1 107 113 (Pubitemid 36555817)
94. Stein J. H., Klein M. A., Bellehumeur J. L., et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation: 2001; 104 3 257 262 (Pubitemid 32666944)
95. de Larrañaga G. F., Petroni A., Deluchi G., Alonso B. S., Benetucci J. A. Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagul Fibrinolysis: 2003; 14 1 15 18 (Pubitemid 36206717)
96. Buonaguro L., Barillari G., Chang H. K., et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol: 1992; 66 12 7159 7167
97. Dhawan S., Puri R. K., Kumar A., Duplan H., Masson J. M., Aggarwal B. B. Human immunodeficiency virus-1-tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells. Blood: 1997; 90 4 1535 1544 (Pubitemid 27355425)
98. Calza L., Verucchi G., Pocaterra D., et al. Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. Int J STD AIDS: 2009; 20 10 683 689
99. Coll B., Parra S., Alonso-Villaverde C., et al. HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine: 2006; 34 1-2 51 55 (Pubitemid 43817552)
100. Guaraldi G., Stentarelli C., Zona S., et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis: 2010; 208 1 222 227
101. Eugenin E. A., Morgello S., Klotman M. E., et al. Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease. Am J Pathol: 2008; 172 4 1100 1111 (Pubitemid 351520006)
102. O'Connor C. M., Dunne M. W., Pfeffer M. A., et al. Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA: 2003; 290 11 1459 1466 (Pubitemid 37430400)
103. Grayston J. T., Kronmal R. A., Jackson L. A., et al. ACES Investigators. Azithromycin for the secondary prevention of coronary events. N Engl J Med: 2005; 352 16 1637 1645 (Pubitemid 40530230)
104. Cannon C. P., Braunwald E., McCabe C. H., et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med: 2005; 352 16 1646 1654 (Pubitemid 40530231)
105. Jespersen C. M., Als-Nielsen B., Damgaard M., et al. CLARICOR Trial Group. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ: 2006; 332 7532 22 27
106. Danesh J. Antibiotics in the prevention of heart attacks. Lancet: 2005; 365 9457 365 367 (Pubitemid 40179212)
107. Epstein S. E., Zhu J., Najafi A. H., Burnett M. S. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation: 2009; 119 24 3133 3141
108. Grayston J. T. Chlamydia pneumoniae and atherosclerosis. Clin Infect Dis: 2005; 40 8 1131 1132 (Pubitemid 40490237)
109. Beatty W. L., Morrison R. P., Byrne G. I. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev: 1994; 58 4 686 699
110. Kutlin A., Roblin P. M., Hammerschlag M. R. Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. Antimicrob Agents Chemother: 2002; 46 2 409 412 (Pubitemid 34087188)
111. Gieffers J., Füllgraf H., Jahn J., et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation: 2001; 103 3 351 356 (Pubitemid 32105972)